CARsgen Therapeutics Holdings Limited
CARsgen Therapeutics Holdings Limited (HKSE: 2171) is trading at HK$12.45, about ₹153 at today's HKD/INR rate, as of 29 Sep 2026, 4:08 AM ET, up 2.13% today. Indian residents can buy CARsgen Therapeutics from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$12.19
Today's high
HK$12.75
52 week low
HK$10.87
52 week high
HK$28.60
2171 opened at HK$12.19, closed previously at HK$12.19, and has traded between HK$10.87 and HK$28.60 over the past 52 weeks.
About
CARsgen Therapeutics Holdings Limited, a biopharmaceutical firm founded in Shanghai, China, in 2014, focuses on the discovery, development, and commercialization of advanced chimeric antigen receptor T (CAR-T) cell therapies. The company's efforts are directed toward treating various hematological malignancies and solid tumors across China and the United States. Its robust pipeline includes several key candidates: CT053, an autologous CAR-T product, is currently in a pivotal Phase II trial in China for relapsed/refractory multiple myeloma. Additionally, CT041, another autologous CAR-T, is undergoing Phase Ib/II clinical trials for advanced gastric/gastroesophageal junction and pancreatic cancers in China, and Phase Ib trials for comparable indications in the U.S. CARsgen is also advancing CT011, an autologous CAR-T candidate, through Phase I for patients with Glypican-3 positive advanced hepatocellular carcinoma, and CT032, an autologous CAR-T, in Phase I/II for B cell Non-Hodgkin's lymphoma in China. Furthermore, its pipeline features AB011, a humanized monoclonal antibody in Phase I for CLDN18.2 positive solid tumors in China, as well as CT017, an autologous Glypican-3-targeted CAR-T for hepatocellular carcinoma, and other promising therapies for solid tumors.
Key statistics
Avg. volume
4.25M
Market cap
HK$7.09B
P/E Ratio
-66.23
Price-to-sales ratio
44.34
Enterprise value
CN¥4.73B
Free cash flow yield
-3.08%
Debt-to-equity ratio
0.07
Return on equity
-9.45%
ROIC
-7.05%
Beta
0.26
Dividend yield
0.00%
Last dividend
HK$0.00
Financial overview
Revenue
CN¥125.66M
Earnings per share
-CN¥0.18
Free cash flow
-CN¥243.03M
Net profit margin
-65.17%
Gross margin
67.78%
EBITDA
-CN¥203.91M
Revenue growth
218.74%
Similar securities
This is not an investment recommendation
How to buy CARsgen Therapeutics from India
Indian residents can buy CARsgen Therapeutics shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for CARsgen Therapeutics and place an order
Find CARsgen Therapeutics by name or by its ticker, 2171, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. CARsgen Therapeutics trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your CARsgen Therapeutics position in HKD and INR. CARsgen Therapeutics pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in CARsgen Therapeutics from India
Trading and taxes when buying CARsgen Therapeutics from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneCARsgen Therapeutics does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy CARsgen Therapeutics stock?
Yes. CARsgen Therapeutics (2171) has been listed on the Hong Kong Stock Exchange since 2021, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one CARsgen Therapeutics share cost in rupees?
One CARsgen Therapeutics share is HK$12.45 — about ₹153 at an HKD/INR rate of 12.25 on 28 Sep 2026. Both the CARsgen Therapeutics price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying CARsgen Therapeutics from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of CARsgen Therapeutics?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on CARsgen Therapeutics shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the CARsgen Therapeutics price. Paasa issues a capital-gains statement for your return.
Does CARsgen Therapeutics pay a dividend?
No. CARsgen Therapeutics does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade CARsgen Therapeutics from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is CARsgen Therapeutics a Hong Kong SAR China company, and does that change how it is taxed?
CARsgen Therapeutics trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. CARsgen Therapeutics trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare CARsgen Therapeutics shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your CARsgen Therapeutics holding, its cost and its closing value.
How do I sell CARsgen Therapeutics and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.